Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Diamminedichloroplatinum
Drug ID BADD_D00643
Description Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Indications and Usage For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
Marketing Status approved
ATC Code L01XA01
DrugBank ID DB00515
KEGG ID D00275
MeSH ID D002945
PubChem ID 441203
TTD Drug ID D08ZRW
NDC Product Code 16729-288; 25021-253; 0143-9505; 68554-0077; 0143-9504; 68001-283; 44567-509; 50711-0001; 44567-510; 63323-103; 0703-5747; 0703-5748; 44567-530; 60505-6277; 68083-163; 44567-511; 49452-2078; 54875-0001; 67184-0010; 68083-162; 70860-206; 49812-0009; 72659-864
UNII Q20Q21Q62J
Synonyms Cisplatin | cis-Diamminedichloroplatinum(II) | Platinum Diamminodichloride | Diamminodichloride, Platinum | cis-Platinum | cis Platinum | Dichlorodiammineplatinum | cis-Diamminedichloroplatinum | cis Diamminedichloroplatinum | cis-Dichlorodiammineplatinum(II) | NSC-119875 | Platino | Platinol | Biocisplatinum | Platidiam
Chemical Information
Molecular Formula Cl2H6N2Pt+2
CAS Registry Number 15663-27-1
SMILES N.N.Cl[Pt+2]Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acute leukaemia16.01.02.001; 01.10.02.001--Not Available
Ageusia17.02.07.001; 07.14.03.003--Not Available
Alopecia23.02.02.001--
Amnesia19.20.01.001; 17.03.02.001--
Amylase increased13.05.01.009--
Anaemia01.03.02.001--
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Anxiety19.06.02.002--
Areflexia17.02.01.001--Not Available
Arrhythmia02.03.02.001--Not Available
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.001--Not Available
Azoospermia21.03.03.001--
Blindness06.02.10.003; 17.17.01.003--Not Available
Blindness cortical06.02.10.004; 17.17.01.017--Not Available
Blood creatinine increased13.13.01.004--
Blood uric acid increased13.02.04.001--Not Available
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.002--Not Available
Cardiac failure congestive02.05.01.002--Not Available
Cellulitis23.11.02.004; 11.02.01.001--Not Available
Cerebral arteritis17.08.02.004; 24.12.02.002--Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Clonus17.02.05.002--Not Available
Conjunctivitis11.01.06.012; 06.04.01.002--
Coronary artery disease24.04.04.006; 02.02.01.001--Not Available
Deafness04.02.01.001--Not Available
Dehydration14.05.05.001--
Dermatitis23.03.04.002--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 5 Pages